Work

Cell therapy must be regulated as medicine

Year: 2015

Type: editorial

Abstract: Background The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy. Case presentation We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens. Conclusion This highly refractory pre-B Ph− ALL was induced to complete remission after one course of single agent blinatumomab.

Source: Experimental Hematology and Oncology

DOI: 10.1186/s40164-016-0055-0

Authors: Zihai Li, Delong Liu

Institutions: Medical University of South Carolina, MUSC Hollings Cancer Center, New York Medical College

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,290